These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12839625)

  • 1. Clinico-pathogenetic findings and management of chondrodystrophic myotonia (Schwartz-Jampel syndrome): a case report.
    Ho NC; Sandusky S; Madike V; Francomano CA; Dalakas MC
    BMC Neurol; 2003 Jul; 3():3. PubMed ID: 12839625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schwartz Jampel syndrome responding positively to carbamazepine therapy: a case report and a novel mutation.
    Gürbüz G; Albayrak HM
    Turk J Pediatr; 2019; 61(6):967-970. PubMed ID: 32134596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia).
    Nicole S; Davoine CS; Topaloglu H; Cattolico L; Barral D; Beighton P; Hamida CB; Hammouda H; Cruaud C; White PS; Samson D; Urtizberea JA; Lehmann-Horn F; Weissenbach J; Hentati F; Fontaine B
    Nat Genet; 2000 Dec; 26(4):480-3. PubMed ID: 11101850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical and genetic features of Schwartz-Jampel syndrome in a Chinese child: case report and literature review].
    Dai L; Fang F; Huang Y; Cheng H; Ren C
    Zhonghua Er Ke Za Zhi; 2015 Nov; 53(11):855-9. PubMed ID: 26758326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural and functional mutations of the perlecan gene cause Schwartz-Jampel syndrome, with myotonic myopathy and chondrodysplasia.
    Arikawa-Hirasawa E; Le AH; Nishino I; Nonaka I; Ho NC; Francomano CA; Govindraj P; Hassell JR; Devaney JM; Spranger J; Stevenson RE; Iannaccone S; Dalakas MC; Yamada Y
    Am J Hum Genet; 2002 May; 70(5):1368-75. PubMed ID: 11941538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schwartz-Jampel syndrome and perlecan deficiency.
    Stum M; Davoine CS; Fontaine B; Nicole S
    Acta Myol; 2005 Oct; 24(2):89-92. PubMed ID: 16550923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A missense mutation in domain III in HSPG2 in Schwartz-Jampel syndrome compromises secretion of perlecan into the extracellular space.
    Iwata S; Ito M; Nakata T; Noguchi Y; Okuno T; Ohkawara B; Masuda A; Goto T; Adachi M; Osaka H; Nonaka R; Arikawa-Hirasawa E; Ohno K
    Neuromuscul Disord; 2015 Aug; 25(8):667-71. PubMed ID: 26031903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Schwartz-Jampel syndrome(chondrodystrophic myotonia)].
    Arikawa-Hirasawa E
    Ryoikibetsu Shokogun Shirizu; 2001; (35):126-9. PubMed ID: 11555888
    [No Abstract]   [Full Text] [Related]  

  • 9. Identification of a novel splice site HSPG2 mutation and prenatal diagnosis in Schwartz Jampel Syndrome type 1 using whole exome sequencing.
    Das Bhowmik A; Dalal A; Matta D; Kandadai RM; Kanikannan MA; Aggarwal S
    Neuromuscul Disord; 2016 Nov; 26(11):809-814. PubMed ID: 27521129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schwartz-Jampel syndrome (chondrodystrophic myotonia).
    Viljoen D; Beighton P
    J Med Genet; 1992 Jan; 29(1):58-62. PubMed ID: 1552548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chondrodystrophic myotonia (Schwartz-Jampel syndrome) in South African children.
    Moodley M; Moosa A
    Neuropediatrics; 1990 Nov; 21(4):206-10. PubMed ID: 2290482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spectrum of HSPG2 (Perlecan) mutations in patients with Schwartz-Jampel syndrome.
    Stum M; Davoine CS; Vicart S; Guillot-Noël L; Topaloglu H; Carod-Artal FJ; Kayserili H; Hentati F; Merlini L; Urtizberea JA; Hammouda el-H; Quan PC; Fontaine B; Nicole S
    Hum Mutat; 2006 Nov; 27(11):1082-91. PubMed ID: 16927315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel HSPG2 mutations causing Schwartz‑Jampel syndrome type 1 in a Chinese family: A case report.
    Yan W; Dai J; Shi D; Xu X; Han X; Xu Z; Chen D; Teng H; Jiang Q
    Mol Med Rep; 2018 Aug; 18(2):1761-1765. PubMed ID: 29901129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity in Schwartz-Jampel chondrodystrophic myotonia.
    Giedion A; Boltshauser E; Briner J; Eich G; Exner G; Fendel H; Kaufmann L; Steinmann B; Spranger J; Superti-Furga A
    Eur J Pediatr; 1997 Mar; 156(3):214-23. PubMed ID: 9083764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chondrodystrophic myotonia (Schwartz-Jampel syndrome): report of a new case and follow-up of patients initially reported in 1969.
    Edwards WC; Root AW
    Am J Med Genet; 1982 Sep; 13(1):51-6. PubMed ID: 7137221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidisciplinary approach to the treatment of a patient with chondrodystrophic myotonia (Schwartz-Jampel vel Aberfeld syndrome): case report and literature review.
    Nessler M; Puchala J; Kwiatkowski S; Kobylarz K; Mojsa I; Chrapusta-Klimeczek A
    Ann Plast Surg; 2011 Sep; 67(3):315-9. PubMed ID: 21263291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of a Schwartz-Jampel syndrome case.
    Kuliński W; Burak M; Michalska A
    Wiad Lek; 2018; 71(7):1429-1432. PubMed ID: 30448822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schwartz-Jampel syndrome. A case report.
    Dhanrajani PJ; Abdulwassie HM
    Indian J Dent Res; 1996; 7(3):107-9. PubMed ID: 9495126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of myotonia with carbamazepine in three cases with the Schwartz-Jampel syndrome.
    Topaloğlu H; Serdaroğlu A; Okan M; Gücüyener K; Topçu M
    Neuropediatrics; 1993 Aug; 24(4):232-4. PubMed ID: 8232784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the heparan sulfate proteoglycan perlecan on human disease and health.
    Arikawa-Hirasawa E
    Am J Physiol Cell Physiol; 2022 Jun; 322(6):C1117-C1122. PubMed ID: 35417267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.